SLP will partner with the University of Pittsburgh and its Liver-on-a-Chip platform
Simulations Plus Hosts the 2022 Model-Informed Drug Development (MIDD+) Scientific Conference
Attendees from 57 Countries Spend Two Days Focused on Advancing Model-Informed Drug Development
Simulations Plus Sets Date for Second Quarter Fiscal Year 2022 Earnings Release and Conference Call
Conference Call to be on Wednesday, April 6, 2022, at 5:00 PM ET
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit National Organization for Rare Disorders
Improving access to treatment in the lives of individuals and families affected by rare diseases
Simulations Plus Releases MembranePlus™ 3.0
New functionality for transdermal products creates a state-of-the-art IVIVE methodology in combination with the GastroPlus TCAT platform
Simulations Plus Extends its Distributor Agreement in Japan with Northern Science Consulting for Monolix™
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced...
Simulations Plus to Present at Oppenheimer Annual Healthcare Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy,
Simulations Plus to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be participating in BTIG’s MedTech
Simulations Plus Partners with Large Pharmaceutical Company to Drive Advancements to the GastroPlus Mechanistic Oral Absorption Model
Collaborative research effort will further enhance the ACAT model to aid scientists in the detailed understanding of local drug disposition in the gastrointestinal tract
Simulations Plus Enters New Collaboration with Leading Animal Health Company
Partnership will expand virtual animal models to support veterinary medicine and next-generation alternatives to animal testing
Simulations Plus Reports First Quarter Fiscal 2022 Financial Results
Total revenue growth of 16%; Software revenue growth of 19%; Diluted Earnings Per Share (EPS) growth of 25%
Board of Directors announces quarterly dividend of $0.06 per share
Simulations Plus Sets Date for First Quarter Fiscal Year 2022 Earnings Release and Conference Call
Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the first quarter of fiscal year 2022, the period ended November 30, 2021, after the close... January 6, 2022.
Lixoft Adds New Bioequivalence Module in MonolixSuite® Version 2021R1
Update includes enhanced PKanalix, Monolix, and Simulx modules
Simulations Plus Sets Date for First Quarter Fiscal Year 2022 Earnings Release and Conference Call
Conference Call to be on Thursday, January 6, 2022, at 5:00 PM ET
Simulations Plus Extends its Distributor Agreement in Japan with Northern Science Consulting for Monolix™
Complementing the existing distributorship with ADMET Predictor® and GastroPlus® software
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope
Expanding access to high-quality medication for people in need
Simulations Plus Names Sharlene Evans to Board of Directors
Experienced Human Resource, Development and Organizational Leader Bolsters Board